Literature DB >> 24179111

Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants.

F Lutwama1, B M Kagina, A Wajja, F Waiswa, N Mansoor, S Kirimunda, E J Hughes, N Kiwanuka, M L Joloba, P Musoke, T J Scriba, H Mayanja-Kizza, C L Day, W A Hanekom.   

Abstract

BACKGROUND: In Uganda, the tuberculosis vaccine BCG is administered on the first day of life. Infants delivered at home receive BCG vaccine at their first healthcare facility visit at 6 weeks of age. Our aim was to determine the effect of this delay in BCG vaccination on the induced immune response.
METHODS: We assessed CD4(+) and CD8(+) T-cell responses with a 12-hour whole-blood intracellular cytokine/cytotoxic marker assay, and with a 6-day proliferation assay.
RESULTS: We enrolled 92 infants: 50 had received BCG vaccine at birth and 42 at 6 weeks of age. Birth vaccination was associated with (1) greater induction of CD4(+) and CD8(+) T cells expressing either interferon γ (IFN-γ) alone or IFN-γ together with perforin and (2) induction of proliferating cells that had greater capacity to produce IFN-γ, tumor necrosis factor α (TNF-α), and interleukin 2 together, compared with delayed vaccination.
CONCLUSIONS: Distinct patterns of T-cell induction occurred when BCG vaccine was given at birth and at 6 weeks of age. We propose that this diversity might impact protection against tuberculosis. Our results differ from those of studies of delayed BCG vaccination in South Africa and the Gambia, suggesting that geographical and population heterogeneity may affect the BCG vaccine-induced T-cell response.

Entities:  

Keywords:  BCG; CD4+ and CD8+ T-cell responses; Uganda; birth; delayed; vaccination

Mesh:

Substances:

Year:  2013        PMID: 24179111      PMCID: PMC6392474          DOI: 10.1093/infdis/jit570

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Bacillus Calmette-Guérin vaccination at birth and in vitro cytokine responses to non-specific stimulation. A randomized clinical trial.

Authors:  T N Nissen; N M Birk; B A Blok; R J W Arts; A Andersen; J Kjærgaard; L M Thøstesen; T Hoffmann; D L Jeppesen; S D Nielsen; P-E Kofoed; L G Stensballe; P Aaby; M Ruhwald; M G Netea; C S Benn; O Pryds
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-09-10       Impact factor: 3.267

2.  Exploiting Pre-Existing CD4+ T Cell Help from Bacille Calmette-Guérin Vaccination to Improve Antiviral Antibody Responses.

Authors:  Tony W Ng; Ariel S Wirchnianski; Anna Z Wec; J Maximilian Fels; Christopher T Johndrow; Kevin O Saunders; Hua-Xin Liao; John Chan; William R Jacobs; Kartik Chandran; Steven A Porcelli
Journal:  J Immunol       Date:  2020-06-08       Impact factor: 5.422

Review 3.  Factors influencing innate immunity and vaccine responses in infancy.

Authors:  Beate Kampmann; Christine E Jones
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-19       Impact factor: 6.237

4.  Age at Mycobacterium bovis BCG Priming Has Limited Impact on Anti-Tuberculosis Immunity Boosted by Respiratory Mucosal AdHu5Ag85A Immunization in a Murine Model.

Authors:  Daniela Damjanovic; Amandeep Khera; Sam Afkhami; Rocky Lai; Anna Zganiacz; Mangalakumari Jeyanathan; Zhou Xing
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

5.  Investigating the non-specific effects of BCG vaccination on the innate immune system in Ugandan neonates: study protocol for a randomised controlled trial.

Authors:  Sarah Prentice; Emily L Webb; Hazel M Dockrell; Pontiano Kaleebu; Alison M Elliott; Stephen Cose
Journal:  Trials       Date:  2015-04-11       Impact factor: 2.279

6.  Minimal Sex-Differential Modulation of Reactivity to Pathogens and Toll-Like Receptor Ligands following Infant Bacillus Calmette-Guérin Russia Vaccination.

Authors:  Fatoumatta Darboe; Jane U Adetifa; John Reynolds; Safayet Hossin; Magdalena Plebanski; Mihai G Netea; Sarah L Rowland-Jones; Jayne S Sutherland; Katie L Flanagan
Journal:  Front Immunol       Date:  2017-09-08       Impact factor: 7.561

Review 7.  What Have We Learnt about BCG Vaccination in the Last 20 Years?

Authors:  Hazel M Dockrell; Steven G Smith
Journal:  Front Immunol       Date:  2017-09-13       Impact factor: 7.561

8.  Study of the BCG Vaccine-Induced Cellular Immune Response in Schoolchildren in Antananarivo, Madagascar.

Authors:  Paulo Ranaivomanana; Vaomalala Raharimanga; Patrice M Dubois; Vincent Richard; Voahangy Rasolofo Razanamparany
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

9.  Factors affecting immunogenicity of BCG in infants, a study in Malawi, The Gambia and the UK.

Authors:  Yun-Gyoung Hur; Patricia Gorak-Stolinska; Maeve K Lalor; Hazzie Mvula; Sian Floyd; John Raynes; Anne Ben-Smith; Joseph R Fitchett; Katie L Flanagan; Sarah Burl; Martin O Ota; Amelia C Crampin; Steven G Smith; Hazel M Dockrell
Journal:  BMC Infect Dis       Date:  2014-04-05       Impact factor: 3.090

10.  Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.

Authors:  Elisa Nemes; Anneke C Hesseling; Michele Tameris; Katya Mauff; Katrina Downing; Humphrey Mulenga; Penelope Rose; Marieke van der Zalm; Sharon Mbaba; Danelle Van As; Willem A Hanekom; Gerhard Walzl; Thomas J Scriba; Helen McShane; Mark Hatherill
Journal:  Clin Infect Dis       Date:  2018-02-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.